Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Monsanto Company and Complix NV Sign Collaboration

Published: Friday, September 21, 2012
Last Updated: Thursday, September 20, 2012
Bookmark and Share
Collaboration agreement to develop Complix’s proprietary Alphabody® protein technology in the field of agriculture.

Monsanto Company and Complix NV have announced that they have entered into a collaboration agreement to evaluate and develop Complix’s proprietary Alphabody® protein technology in the field of agriculture.

Complix is a biopharmaceutical company focused on the discovery and development of its Alphabody® technology platform.

Alphabodies are a unique class of protein therapeutics that are potentially active against a broad range of disease targets, including intracellular targets.

Alphabodies are small single chain alpha-helical proteins that are designed by computer modelling, but are inspired by naturally existing protein structures. This collaboration represents the first application of Complix’s Alphabody® technology in agriculture.

“Complix’s expertise in protein targeting technology offers a novel platform to further enhance our trait development capabilities,” said Bob Reiter, Monsanto’s Vice President of Biotechnology.

Reiter continued, “We believe this technology offers great promise and could contribute to development of new traits to protect plants from pests and diseases. We are pleased to work with Complix to develop this promising technology in a way that might deliver on-farm benefits to our grower customers.”

Under the terms of the agreement, Complix will grant Monsanto worldwide exclusive rights to access Complix’s Alphabody® platform technology for use in plant agriculture.

Complix retains the exclusive rights on any discoveries made under this collaboration for use outside the field of plant agriculture.

The agreement also includes options to expand the collaboration across multiple applications within plant agriculture. Further terms were not disclosed.

“We are delighted to have concluded this agreement with Monsanto, a leading agricultural company with a strong track record of delivering innovations to the marketplace,” said Mark Vaeck, Chief Executive Officer of Complix NV.

Vaeck continued, “By working with Monsanto, our partner of choice for this space, I am confident that we will be able to apply our Alphabody platform to address some of the most important challenges facing agriculture today and tomorrow. This strategic alliance, will also enable us to create significant value for our shareholders as it will contribute to further strengthening and expanding our Alphabody platform and help Complix to establish its leadership position in the field of cross-over therapeutics.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
New Imaging Technique in Alzheimer’s Disease
Study confirms new imaging technique corresponds a higher degree of actual brain changes.
Ancient Eggshell Protein Breaks Through DNA Time Barrier
Fossil proteins from a 3.8million year-old eggshell have been identifed, suggests proteins could give insight into evolutionary tree.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Protein Studies Discover Molecular Secrets
Two protein studies have mapped proteins that reveal the secrets to recycling carbon and healing cells.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Death-or-Repair Switch Protein Identified
Researchers have identified a protein that plays a key role in the decision process of cell damage repair or cellular suicide.
Gene Deletion Reveals Cell Secrets
Researchers have deleted 174 genes in yeast to analyse the effect of individual gene deletion.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!